Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

A comprehensive analysis of two types of xenogeneic bone particles for use in maxillofacial bone regeneration therapies

Ortiz-Arrabal O., Rodriguez MA., Chato-Astrain J., Martín-Piedra MÁ., Garzón I., Carriel V.

Prospective Study on Face & Skin, published in PLoS One (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
PLoS One (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40388466
PMCID
PMC12088006
DOI
10.1371/journal.pone.0323754
Citations
1

Abstract (original English)

Regeneration of maxillofacial bone structures is challenging. One strategy for bone damage repair involves using bone filler particles. This study analyzed the regenerative potential of deproteinized bone particles (DP) and collagen-based bone particles (CP) to determine the effectiveness of each biomaterial in bone repair. Structural analysis using scanning electron microscopy and 3D scanning showed that DP and CP were structurally similar, comprising a heterogeneous mixture of bone particles of varying sizes and shapes. Ex vivo analyses, including morphological evaluation, LIVE & DEAD assays, and DNA quantification, demonstrated high biocompatibility of CP and DP with human cells in both direct and indirect contact at 24, 48, and 72 hours. Both particles were grafted onto Wistar rats with a critical mandibular defect for two months. Computed tomography revealed significant defect reduction in the CP group, but not in the DP group, compared to negative controls without any bone particles. Histological analysis showed biocompatibility of both particles in vivo and identified regenerative tissue with collagen fibers and mineralized spots in CP and DP, with more mineralized spots in DP. Histochemistry and immunohistochemistry confirmed collagen, proteoglycans, and osteocalcin presence in the regeneration area of CP and DP. These results confirm the biocompatibility and potential

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
MandibleAnimalsHumansRatsRats, WistarCollagenBiocompatible MaterialsBone SubstitutesBone TransplantationBone Regeneration

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research